Bausch + Lomb Nabs ISTA (ISTA, VRX)
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Last December Valeant Pharmaceuticals Inc. (NYSE: VRX) made a hostile offer of $6.50/share which it eventually raised to $7.50 with a target price of $8.50 provided that the due diligence was completed satisfactorily. ISTA said it would evaluate Valeant’s offer, but would keep its options open. Valeant later withdrew its offer.
The all-cash deal is expected to close in the second quarter.
ISTA’s shares are trading higher in the pre-market this morning, at $9.02 up about 7.6%.
Contact [email protected] for any questions or corrections.